DOI QR코드

DOI QR Code

Combined Germline Variations of Thrombophilic Genes Promote Genesis of Lung Cancer

  • Ozen, Filiz (Department of Medical Genetics, Faculty of Medicine, Cumhuriyet University) ;
  • Polat, Fikriye (Department of Elementary Sciences Education, Faculty of Education, Kocaeli University) ;
  • Arslan, Sulhattin (Department of Cheast, Faculty of Medicine, Cumhuriyet University) ;
  • Ozdemir, Ozturk (Department of Medical Genetics, Faculty of Medicine, Cumhuriyet University)
  • Published : 2013.09.30

Abstract

Background: A large variety of familiar and non-familiar lung carcinomas (LC) are caused by long term exposure to chemical carcinogens that are present in tobacco smoke. We aimed to investigate the prevalence of 5 thrombophilic germ-line mutations in patients with lung carcinomas. Materials and Methods:A total of 52 LC patients and 212 healthy controls from same population were analyzed for FV Leiden, factor V H1299R (R2), PAI-1, MTHFR C677T, MTHFR A1298C, ACE I/D, and Apo E genes and compared. Results: Overall, heterozygous and/or homozygous point mutations in FV Leiden Apo E2, PAI-1 and MTHFR C677T genes were associated with LC in the current cohort. There was no meaningful association between LC and ACE I/D gene markers. Conclusions: The current results showed that LC is related to combined thrombophilic gene mutations and individuals with homozygosity of 4G in PAI-1 and MTHFR C677T genes and heterozygosity of FV Leiden, Apo E4 genes have a germ-line risk for LC tumorigenesis.

Keywords

A case control study;combined thrombophilic genes;lung cancer;germ-line variations

References

  1. Alberola V, Sarries C, Rosell R, et al (2004). Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV nonsmall- cell lung cancer. Clin Lung Cancer, 5, 360-5. https://doi.org/10.3816/CLC.2004.n.014
  2. Arslan S, Karadayi S, Yildirim ME, et al (2011). The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep, 38, 991-6. https://doi.org/10.1007/s11033-010-0194-z
  3. Bakan N, Bakan E, Süerdem M, et al (1988). Serum zinc and angiotensin-converting enzyme levels in patients with lung cancer. Biofactors, 1, 177-8.
  4. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J (2004). Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis. Int J Mol Med, 13, 759-66.
  5. Bennet AM, Di Angelantonio E, Ye Z, et al (2007). Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA, 298, 1300-11. https://doi.org/10.1001/jama.298.11.1300
  6. Blom JW, Doggen CJ, Osanto S, et al (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293, 715-22. https://doi.org/10.1001/jama.293.6.715
  7. Bruggemann LW, Versteeg HH, Niers TM, et al (2008). Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med, 12, 2622-7. https://doi.org/10.1111/j.1582-4934.2008.00316.x
  8. Couraud S, Zalcman G, Milleron B, et al (2012). Lung cancer in never smokers--a review. Eur J Cancer, 48, 1299-311. https://doi.org/10.1016/j.ejca.2012.03.007
  9. Cui LH, Shin MH, Kim HN, et al (2011). Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population. BMC Med Genetics, 12, 28.
  10. Cui LH, Yu Z, Zhang TT, et al (2011). Influence of polymorphisms in MTHFR 677 CgT, TYMS 3Rg2R and MTR 2756 AgG on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics, 12, 797-808. https://doi.org/10.2217/pgs.11.27
  11. Dahlback B (2008). Advances in understanding pathogenic mechanisms of thrombophilic disorders. BLOOD, 112, 19-27. https://doi.org/10.1182/blood-2008-01-077909
  12. Devic-Pavlic S, Ristic S, Flego V, et al (2012). Angiotensinconverting enzyme insertion/deletion gene polymorphism in lung cancer patients. Genet Test Mol Biomarkers, 16, 722-5. https://doi.org/10.1089/gtmb.2011.0306
  13. Feng Y, Ni L, Wan H, et al (2011). Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep, 26, 1157-64.
  14. Gao S, Liu N, Ma Y, et al (2012). Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk. Asian Pac J Cancer Prev, 13, 569-73. https://doi.org/10.7314/APJCP.2012.13.2.569
  15. Gao M, Wang Y, Shi Y, et al (2012). The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk: a case-control study and a meta-analysis. J Renin Angiotensin Aldosterone Syst, 13, 455-60. https://doi.org/10.1177/1470320312443912
  16. Kiyohara C, Horiuchi T, Takayama K, et al (2011). Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population. BMC Cancer, 11, 459. https://doi.org/10.1186/1471-2407-11-459
  17. Lam TK, Rotunno M, Ryan BM, et al (2013). Heme-related gene expression signatures of meat intakes in lung cancer tissues. Mol Carcinog, [Epub ahead of print].
  18. Lee MS, Asomaning K, Su L, et al (2012). MTHFR polymorphisms, folate intake and carcinogen DNA adducts in the lung. Int J Cancer, 131, 1203-9. https://doi.org/10.1002/ijc.27338
  19. Li CH, Cai L, Chen XS, et al (2008). DDP-sensitivity-related genes in 10 lung cancer cell lines. Zhonghua Zhong Liu Za Zhi, 30, 418-21.
  20. Liu CS, Tsai CW, Hsia TC, et al (2009). Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics and Proteomics, 6, 325-30.
  21. Nacak M, Nacak I, Sanli M, et al (2010). Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer Genetics and Cytogenetics, 198, 22-6. https://doi.org/10.1016/j.cancergencyto.2009.11.019
  22. Offersen BV, Pfeiffer P, Andreasen P, et al (2007). Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer, 56, 43-50. https://doi.org/10.1016/j.lungcan.2006.11.018
  23. Shetty S, Idell S, (2000). Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol Lung Cell Mol Physiol, 278, 148-56. https://doi.org/10.1152/ajplung.2000.278.1.L148
  24. Onitilo AA, Doi SA, Engel JM, et al (2013). Relationship between Factor V Leiden mutation and venous thromboembolism in patients with breast cancer treated with tamoxifen. Thromb Res, 131, 567-8. https://doi.org/10.1016/j.thromres.2013.01.035
  25. Pavey SJ, Marsh NA, Ray MJ, et al (1996). Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. Boll Soc Ital Biol Sper, 72, 331-40.
  26. Prasad VV, Wilkhoo H, (2011). Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie, 34, 422-6. https://doi.org/10.1159/000331131
  27. Shetty S, Shetty P, Idell S, et al (2008). Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem, 283, 19570-80. https://doi.org/10.1074/jbc.M710268200
  28. Siemianowicz K, Gminski J, Garczorz W, et al (2003). Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and nonsmall cell lung cancer. Oncol Rep, 10, 1341-4.
  29. Stankova J, Shang J, Rozen R (2005). Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res, 11, 2047-52. https://doi.org/10.1158/1078-0432.CCR-04-2047
  30. Su WP, Chen YT, Lai WW et al (2011). Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer, 71, 28-33. https://doi.org/10.1016/j.lungcan.2010.04.009
  31. Thu KL, Vucic EA, Chari R, et al (2012). Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. CoPLoS One, 7, 33003. https://doi.org/10.1371/journal.pone.0033003
  32. Werle B, Kotzsch M, Lah TT, et al (2004). Plasminogenactivatorinhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res, 24, 4147-61.
  33. Truong T, Sauter W, McKay JD, et al (2010). International lung cancer consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33. https://doi.org/10.1093/carcin/bgq001
  34. Tug E, Aydin H, Kaplan E, et al (2011). Frequency of genetic mutations associated with thromboembolism in the Western Black Sea region. Intern Med, 50, 17-21. https://doi.org/10.2169/internalmedicine.50.4144
  35. Vaissière T, Hung RJ, Zaridze D, et al (2009). Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res, 69, 243-52. https://doi.org/10.1158/0008-5472.CAN-08-2489
  36. Yaren A, Oztop I, Turgut S, et al (2008). Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Experimental Biol Med, 233, 32-7. https://doi.org/10.3181/0705-RM-141
  37. Yenicesu GI, Cetin M, Ozdemir O, et al (2010). A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reproductive Immunol, 63, 126-36.
  38. Zaatari GS, Otrock ZK, Sabbagh AS, et al (2006). Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathol, 38, 442-4. https://doi.org/10.1080/00313020600922934
  39. Zekanowska E, Cieslinski K, Rosc D (2004). Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer. Pneumonol Alergol Pol, 72, 409-14.
  40. Zhang Y, Chen GQ, Ji Y, et al (2012). Ouantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep, 39, 6203-11. https://doi.org/10.1007/s11033-011-1439-1